These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15657349)

  • 1. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma.
    Mohammad RM; Wang S; Aboukameel A; Chen B; Wu X; Chen J; Al-Katib A
    Mol Cancer Ther; 2005 Jan; 4(1):13-21. PubMed ID: 15657349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
    Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
    Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
    Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo.
    Sun Y; Wu J; Aboukameel A; Banerjee S; Arnold AA; Chen J; Nikolovska-Coleska Z; Lin Y; Ling X; Yang D; Wang S; Al-Katib A; Mohammad RM
    Cancer Biol Ther; 2008 Sep; 7(9):1418-26. PubMed ID: 18769131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy.
    Mohammad RM; Al-Katib A; Aboukameel A; Doerge DR; Sarkar F; Kucuk O
    Mol Cancer Ther; 2003 Dec; 2(12):1361-8. PubMed ID: 14707277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, (-)-Gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line.
    Mohammad RM; Wang S; Banerjee S; Wu X; Chen J; Sarkar FH
    Pancreas; 2005 Nov; 31(4):317-24. PubMed ID: 16258364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic cytotoxicity of Bcl-xL inhibitor, gossypol and chemotherapeutic agents in non-Hodgkin's lymphoma cells.
    Li ZM; Jiang WQ; Zhu ZY; Zhu XF; Zhou JM; Liu ZC; Yang DJ; Guang ZZ
    Cancer Biol Ther; 2008 Jan; 7(1):51-60. PubMed ID: 17938578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model.
    Arnold AA; Aboukameel A; Chen J; Yang D; Wang S; Al-Katib A; Mohammad RM
    Mol Cancer; 2008 Feb; 7():20. PubMed ID: 18275607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor.
    Levi E; Zhang L; Aboukameel A; Rishi S; Mohammad RM; Polin L; Hatfield JS; Rishi AK
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1401-13. PubMed ID: 20809119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ApoG2 inhibits antiapoptotic Bcl-2 family proteins and induces mitochondria-dependent apoptosis in human lymphoma U937 cells.
    Sun J; Li ZM; Hu ZY; Lin XB; Zhou NN; Xian LJ; Yang DJ; Jiang WQ
    Anticancer Drugs; 2008 Nov; 19(10):967-74. PubMed ID: 18827561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
    Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
    Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo.
    Lin J; Wu Y; Yang D; Zhao Y
    Oncol Rep; 2013 Aug; 30(2):731-8. PubMed ID: 23708869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma.
    Al-Katib A; Arnold AA; Aboukameel A; Sosin A; Smith P; Mohamed AN; Beck FW; Mohammad RM
    Mol Cancer; 2010 Sep; 9():228. PubMed ID: 20809973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma.
    Paoluzzi L; Gonen M; Gardner JR; Mastrella J; Yang D; Holmlund J; Sorensen M; Leopold L; Manova K; Marcucci G; Heaney ML; O'Connor OA
    Blood; 2008 Jun; 111(11):5350-8. PubMed ID: 18292288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-2 gene expression as a predictor of outcome in diffuse large B-cell lymphoma.
    Shivakumar L; Armitage JO
    Clin Lymphoma Myeloma; 2006 May; 6(6):455-7. PubMed ID: 16796775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gossypol induces Bax/Bak-independent activation of apoptosis and cytochrome c release via a conformational change in Bcl-2.
    Lei X; Chen Y; Du G; Yu W; Wang X; Qu H; Xia B; He H; Mao J; Zong W; Liao X; Mehrpour M; Hao X; Chen Q
    FASEB J; 2006 Oct; 20(12):2147-9. PubMed ID: 16935937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851.
    Gottlieb AJ; Anderson JR; Ginsberg SJ; Bloomfield CD; Norton L; Barcos M; Peterson BA; Nissen N; Henderson ES; Holland JF
    Cancer; 1990 Nov; 66(9):1888-96. PubMed ID: 1699653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance.
    Oliver CL; Miranda MB; Shangary S; Land S; Wang S; Johnson DE
    Mol Cancer Ther; 2005 Jan; 4(1):23-31. PubMed ID: 15657350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
    Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.